Florian Spies

Florian Spies

Auto-generated profile, based on publicly available information

Florian Spies

Department of Cardiology, University Hospital Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in EP Europace
Verified
Journal Article
Closed access
PDF file
SKSven Knecht
Sven Knecht
CSChristian Sticherling
Christian Sticherling
LRLaurent Roten
Laurent Roten
PBPatrick Badertscher
Patrick Badertscher
PKPhilipp Krisai
Philipp Krisai
MKMichael Kühne
Michael Kühne
The aim of the study was to compare the 1-year efficacy and safety of a novel cryoballoon (NCB) ablation system (POLARx; Boston Scientific) for pulmonary vein isolation (PVI) compared with the standard cryoballoon (SCB) system (Arctic Front, Medtronic). Consecutive patients with atrial fibrillation (AF) undergoing PVI using the NCB and the SCB at two centres were included. We report 1-year efficacy after 12 months, short-term safety and hospitalizations within the blanking period, and predictors for AF recurrence. In case of repeat procedures, pulmonary vein (PV) reconnection patterns were characterized. Eighty patients (age 66 ± 10 years, ejection fraction 57 ± 10%, left atrial volume index 39 ± 13 mL/m2, paroxysmal AF in 64%) were studied. After a single procedure and a follow-up of 12 months, 68% in the NCB group and 70% in the SCB group showed no recurrence of AF/atrial tachycardias (P = 0.422). One patient in the NCB group suffered a periprocedural stroke with full recovery. There were no differences regarding hospitalizations during follow-up between the groups. PV reconnection observed during 12 repeat procedures (4 NCB, 8 SCB) pattern was comparable between the groups with more reconnections in the right-sided compared with the left-sided PVs. In this multicentre study comparing two currently available cryoballoon ablation systems for PVI, no differences were observed in the efficacy and safety during a follow-up of 12 months.

28 July 2021 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Open access
PDF file
SKSven Knecht
Sven Knecht
CSChristian Sticherling
Christian Sticherling
LRLaurent Roten
Laurent Roten
PBPatrick Badertscher
Patrick Badertscher
LCLaurève Chollet
Laurève Chollet
MKMichael Kühne
Michael Kühne
Purpose: The aim was to report procedural and technical differences of a novel cryoballoon (NCB) ablation catheter for pulmonary vein isolation (PVI) compared to the standard cryoballoon (SCB) catheter. Methods: Consecutive patients with atrial fibrillation (AF) undergoing PVI using the NCB and the SCB were included. Procedural parameters, technical differences, acute efficacy, and safety are reported. Results: Eighty patients (age 66 ± 10 years, ejection fraction 57 ± 10%, left atrial volume index 40 ± 6 ml/m2) were studied. With the NCB, 156 of 158 PVs (99%) were isolated compared to isolation of 159 of 159 PVs (100%) with the SCB. The median number of freezes in the NCB and the SCB group was 6 (IQR 5–8) and 5 (IQR 4–7), respectively (p = 0.051), with 73% and 71% of the PVs isolated with a single freeze, respectively. Nadir temperature and temperature at isolation were − 59 ± 6 °C and − 45 ± 17 °C in the NCB group and − 46 ± 7 °C and − 32 ± 23 °C in the SCB group, respectively (both p < 0.001) with no difference in time to isolation (TTI). Procedural differences were observed for the total procedure time (84 ± 29 min in the NCB group and 65 ± 17 min in the SCB group, p = 0.003). There was a peri-procedural stroke in one patient in the NCB group. Differences in catheter design were observed that may account for the differences in temperature recordings and ice cap formation. Conclusions: Acute efficacy and TTI were similar with the NCB compared to the SCB. Measured temperatures were lower with the NCB, most likely due to differences in catheter design.

25 July 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
PBPatrick Badertscher
Patrick Badertscher
SKSven Knecht
Sven Knecht
FSFlorian Spies
Florian Spies
CAChloé Auberson
Chloé Auberson
MSMarc Salis
Marc Salis
MKMichael Kühne
Michael Kühne
Background: Despite being the most frequent complication following transcatheter aortic valve replacement (TAVR), optimal management of left bundle‐branch block (LBBB) remains unknown. Electrophysiology study has been proposed for risk stratification. However, the optimal timing of electrophysiology study remains unknown. We aimed to investigate the temporal dynamics of atrioventricular conduction in patients with new‐onset LBBB after TAVR by performing serial electrophysiology study and to deduce a treatment strategy. Methods and Results: We assessed consecutive patients undergoing TAVR via His‐ventricular interval measurement prevalve and postvalve deployment and the day after TAVR. Infranodal conduction delay was defined as a His‐ventricular interval >55 milliseconds. Among 107 patients undergoing TAVR, 53 patients (50%) experienced new‐onset LBBB postvalve deployment and infranodal conduction delay was noted in 24 of 53 patients intraprocedurally (45%). LBBB resolved the day after TAVR in 35 patients (66%). In patients with new‐onset LBBB postvalve deployment and no infrahisian conduction delay intraprocedurally, the His‐ventricular interval did not prolong in any patient to >55 milliseconds the following day. Overall, 4 patients (7.5%) with new‐onset LBBB after TAVR were found to have persistent infrahisian conduction delay 24 hours after TAVR. During 30‐day follow‐up, 1 patient (1.1%) with new LBBB and a normal His‐ventricular interval after TAVR developed new high‐grade atrioventricular block. Conclusions: Among patients with new‐onset LBBB postvalve deployment, infrahisian conduction delay can safely be excluded intraprocedurally, suggesting that early intracardiac intraprocedural conduction studies may be of value in these patients.

18 August 2022 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Open access
PDF file
SKSven Knecht
Sven Knecht
IZIvan Zeljković
Ivan Zeljković
PBPatrick Badertscher
Patrick Badertscher
PKPhilipp Krisai
Philipp Krisai
FSFlorian Spies
Florian Spies
CSChristian Sticherling
Christian Sticherling
Background: Non-pulmonary vein (PV) triggers play a role in the initiation of atrial fibrillation (AF), with the superior vena cava (SVC) being a common location. The aim of the current study was to investigate a strategy of empirical SVC isolation (SVCI) in addition to re-isolation of PV in patients with recurrence of AF after index PV isolation (PVI). Methods: We retrospectively analyzed consecutive patients from two centers with recurrence of AF after index PVI, undergoing a repeat ablation. Whereas only a re-isolation of the PV was intended in patients with reconnections of equal or more than two PV (PVI group), an additional SVCI was aimed for in patients with < 2 isolated PV in addition to the re-isolation of the PV (PVI + group). Analysis was performed as-treated and per-protocol. Results: Of the 344 patients included in the study (age 60 ± 10 years, 73% male, 66% paroxysmal AF), PVI only was performed in 269 patients (77%) and PVI plus SVCI (PVI +) in 75 patients (23%). Overall, freedom from AF/AT after repeat PVI was 80% (196 patients) in the PVI group and 73% in the PVI + group (p = 0.151). In multivariable Cox regression analysis, presence of persistent AF (HR 2.067 (95% CI 1.389–3.078), p < 0.001) and hypertension (HR 1.905 (95% CI 1.218–2.980), p = 0.005) were identified as only significant predictors of AF/AT recurrence. The per-protocol results did not differ from this observation. Conclusions: A strategy of an empirical additional SVCI at repeat PVI ablation for recurrence of AF/AT does not improve outcome compared to a PVI only approach.

1 August 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
NSNicolas Schaerli
Nicolas Schaerli
PBPatrick Badertscher
Patrick Badertscher
FSFlorian Spies
Florian Spies
AMAntonio Madaffari
Antonio Madaffari
SOStefan Osswald
Stefan Osswald
SKSven Knecht
Sven Knecht

30 July 2020 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Open access
PDF file
FSFlorian Spies
Florian Spies
SKSven Knecht
Sven Knecht
IZIvan Zeljković
Ivan Zeljković
TRTobias Reichlin
Tobias Reichlin
AMAntonio Madaffari
Antonio Madaffari
MKMichael Kühne
Michael Kühne
Purpose: PR interval prolongation > 200 ms resulting in the diagnosis of first-degree atrioventricular block (AVB1) is caused by a delay in the AV nodal/His conduction and/or the right intra-atrial conduction (RIAC). The aim of the study was to assess the prevalence of AVB1 due to RIAC delay (AVB1 with normal AH and HV) in patients with atrial fibrillation (AF) and atrial flutter (AFlu). Methods: We included 1067 consecutive patients (33% female, age 63 ± 13 years) referred for catheter ablation of AF (AF-group) (453 patients), AF and AFlu (136 patients), AFlu (292 patients), and AVNRT/AVRT (186 patients). AH-, HV-, PR-interval, and P-wave duration were measured on the 12-lead ECG and the intracardiac electrograms in sinus rhythm. RIAC delay was defined as a prolonged PR interval > 200 ms with normal AH and HV intervals. Results: The prevalence of AVB1 is higher in patients with AFlu (41%) and AF (21%) and patients with both arrhythmias (30%) as compared with a reference group (8%) of patients with AVNRT/AVRT. AVB1 was due to RIAC delay in 42 of 67 patients (63%) in the AF-group, in 37 of 96 patients (39%) in the AFlu-group, and in 17 of 36 patients (47%) in the AF/AFlu group, respectively. AV nodal conduction delay was more common in AFlu patients compared with AF patients. Conclusion: RIAC delay is a common underlying cause of AVB1 in patients with AF and AFlu. These findings may impact the prescription of antiarrhythmic and AV-nodal blocking drugs.